Frates James M

Frates James M is listed in filings as Director at Sage Therapeutics, Inc.. This profile follows SEC Form 4 activity through Mar 9, 2026, including purchase activity and sale activity. Recent filings connect the profile to Sage Therapeutics, Inc. (SAGE) and Amylyx Pharmaceuticals, Inc. (AMLX). The current snapshot covers public activity from Jun 11, 2024 to Mar 9, 2026. Reported amounts are shown as $136.3K to $145.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.